Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Immunon Inc (IMNN) is a clinical-stage biotechnology pioneer developing DNA-based immunotherapies through its proprietary non-viral platform. This page serves as the definitive source for verified company updates, including clinical trial progress, regulatory milestones, and research breakthroughs.
Investors and researchers will find timely updates on key programs like the IMNN-001 ovarian cancer therapy (Phase II completed) and IMNN-101 COVID-19 booster candidate. Our curated news feed covers essential developments including partnership announcements, intellectual property updates, and peer-reviewed study publications.
Content is organized to highlight material events across three core areas: Clinical Trial Advancements, Regulatory Pathway Updates, and Technology Platform Innovations. Each update is vetted for relevance to stakeholders monitoring the company's progress in immuno-oncology and infectious disease applications.
Bookmark this page for structured access to Immunon's official communications, including SEC filings analysis and conference presentation summaries. Check regularly for developments in DNA-based therapeutic approaches that aim to redefine cancer treatment and vaccine development paradigms.
IMUNON (NASDAQ: IMNN) has scheduled a conference call for Monday, May 12, 2025, at 11:00 a.m. ET to discuss its first quarter 2025 financial results and provide updates on its clinical development programs. The company will specifically focus on the progress of IMNN-001, their DNA-based interleukin-12 immunotherapy, including developments toward initiating a Phase 3 clinical trial in advanced ovarian cancer.
Participants can join via phone at 833-816-1132 (North America) or 412-317-0711 (International). The call recording will be available until May 26, 2025, with replay access code 2322959. A webcast will also be accessible and archived online for 90 days.
IMUNON (NASDAQ: IMNN) announced that new survival data from its Phase 2 OVATION 2 Study of IMNN-001 for treating newly diagnosed advanced ovarian cancer will be presented at the 2025 ASCO Annual Meeting (May 30-June 3, Chicago).
The company recently aligned with the FDA on the protocol for the Phase 3 OVATION 3 clinical trial and has begun trial site activation. IMNN-001, based on their TheraPlas® technology platform, is an IL-12 DNA plasmid vector in a nanoparticle delivery system that enables local production of IL-12 protein in the tumor environment.
IMNN-001 is notable as the first and only IL-12 immunotherapy showing clinical effectiveness, including survival benefits, in frontline treatment for advanced (Stage III/IV) ovarian cancer patients. The presentation at ASCO will be delivered by Dr. Premal H. Thaker from Washington University School of Medicine.
IMUNON (NASDAQ: IMNN) has received FDA alignment for its Phase 3 OVATION 3 pivotal trial protocol for IMNN-001, a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer. The trial will evaluate IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy versus standard care.
The study's primary endpoint is overall survival, with secondary endpoints including surgical response score, chemotherapy response score, clinical response, and time to second-line treatment. Recent Phase 2 OVATION 2 data showed IMNN-001 plus NACT improved median overall survival to 46 months, surpassing standard-of-care by 13 months, with an excellent safety profile.
The Phase 3 trial will randomize participants 1:1, focusing on women with newly diagnosed advanced ovarian cancer (stage 3 or 4) eligible for neoadjuvant therapy. HRD-positive participants will receive PARP inhibitors as maintenance therapy.
IMUNON (NASDAQ: IMNN) reported significant progress in 2024 for its DNA-mediated immunotherapy IMNN-001. The company announced robust Phase 2 OVATION 2 Study results showing 13 months overall survival benefit in advanced ovarian cancer patients when combined with chemotherapy. The study demonstrated IMNN-001 as the first immunotherapy to show clinical benefits in both progression-free and overall survival in ovarian cancer.
Key developments include: positive FDA CMC meeting, improved survival data with hazard ratio decreasing from 0.74 to 0.69, and successful End-of-Phase 2 FDA meeting. The company plans to initiate Phase 3 pivotal trial in Q1 2025.
Financial results show a net loss of $18.6 million ($1.62 per share) for 2024, compared to $19.5 million in 2023. Operating expenses decreased 9% to $19.1 million, with R&D expenses at $11.6 million. The company raised $9.1 million through equity offerings in 2024.
IMUNON (NASDAQ: IMNN) has announced new data from its Phase 1 clinical trial of IMNN-101, a DNA plasmid vaccine using their PlaCCine® technology platform. The trial, involving 24 healthy volunteers previously vaccinated against Omicron XBB1.5, demonstrated promising results as a seasonal COVID-19 vaccine.
Key findings include:
- A 2-4 fold increase in neutralizing antibody titers from baseline through Week 4
- Cross-reactivity against XBB1.5 and newer variants
- Safe and well-tolerated profile with no serious adverse effects
- Vaccine stability up to one year at 4°C and one month at 37°C
The vaccine's performance aligns with preclinical results showing over 95% protection in non-human primates, comparable to mRNA vaccines. The company is now seeking potential partners for further development, highlighting IMNN-101's potential as a next-generation vaccine alternative.
IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy, has scheduled its full year 2024 financial results announcement and business update conference call for Thursday, February 27, 2025. The company will release its financial results before U.S. markets open, followed by a conference call at 11:00 a.m. ET.
Investors can participate by dialing 833-816-1132 (North America Toll-Free) or 412-317-0711 (International). The call replay will be available until March 12, 2025, accessible via 877-344-7529 (U.S.), 855-669-9658 (Canada), or 412-317-0088 (International) using code 7147564. A webcast replay will be available for 90 days.
IMUNON (NASDAQ: IMNN) has announced new translational data from its Phase 1/2 OVATION 2 Study of IMNN-001 in advanced ovarian cancer. The study demonstrated a 20% increase in IL-12 levels with the 100mg/m2 dose compared to the 79mg/m2 dose when administered with standard-of-care chemotherapy.
The data showed increased levels of anti-cancer immune cytokines IFN-γ and TNF-α in the tumor microenvironment, with minimal systemic impact. The treatment maintained a favorable safety profile with no serious immune-related adverse events. Previous December 2024 results showed a 13-month improvement in median overall survival with IMNN-001 plus standard care versus standard care alone. More than one-third of patients survived beyond 36 months, with 62% from the IMNN-001 treatment arm.
Following an End-of-Phase 2 FDA meeting, IMUNON is proceeding with a Phase 3 pivotal trial in Q1 2025.
FAQ
What is the current stock price of Imunon (IMNN)?
What is the market cap of Imunon (IMNN)?
